As the NOTCH4 signal pathway is found to be enriched in the Her2 subtype in our study, using NOTCH4 antagonists to suppress NOTCH4 signaling may be a novel and individually distinct strategy to treat Her2 subtype breast cancer. This evidence concerns the gene NOTCH4 and breast carcinoma.